Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr launches generic osteoporosis drug
The FDA has approved generic drug following the expiration of pediatric exclusivity associated with the earliest to expire of the patents listed with the FDA for Fosamax, 70mg
The FDA has approved generic drug following the expiration of pediatric exclusivity associated with the earliest to expire of the patents listed with the FDA for Fosamax, 70mg
Patients receiving once-daily 800mg of IDX899 achieved a mean and median plasma viral load reduction of 2.01 and 2.11 log(10), respectively, after seven days of treatment. Six out
The financial terms of the license agreement includes, an up-front license fee payment to be made by Alphatec to Progressive. Testing, design, regulatory and sales milestone payments that
According to Gary Blick, medical director of Circle Medical, VRX496 appears to cause wt-HIV particles to lose their envelopes and the in vivo pressure delivered by a patient’s
Under the terms of the collaboration, Vermillion will continue to provide financial support, technical assistance and access to its advanced technology platforms, while Johns Hopkins will continue to
In addition to the shares being offered by the company, 83,000 shares will be offered by a selling stockholder. The company will grant the underwriters a 30-day option
In the study, significantly more patients who added vicriviroc 30mg once daily to a new optimized background therapy (OBT) had fully suppressed HIV-RNA (less than 50 copies/ml) at
This agreement expands Meditrina’s clinical stage product portfolio which currently includes Femathina (MPI- 674), an aromatase inhibitor (AI) that Meditrina is repurposing for the treatment of several serious
In BENCHMRK-1 study at 48 weeks, Isentress plus optimized background therapy (OBT) maintained suppression of HIV RNA levels below 400 copies/mL in 74% of patients (170 out of
This nanohydroxyapatite-based bone graft substitute is said to provide a supporting structure for new bone formation and aid bone healing in places where voids or gaps exists in